In today’s increasingly interconnected and globalised world, strategic alliances are key drivers for growth and innovation.We facilitate in-licensing and out-licensing partnerships that bring together companies with complementary competencies to strengthen pipelines, achieve economies of scale, advance technologies, and introduce commercial products to market.
With a robust biologics portfolio of finished products as well as bulk from our strategic partners, we make a staged backward integration project viable. Many of our clients have secured long-term supply contracts with the government in countries where local manufacturing is supported by the authorities. We also support international specialty pharmaceutical companies looking to advance their assets in newer markets through partnerships with local pharmaceutical companies and distributors, providing support for regulatory approval and commercialization of the products in each market.
A typical staged backward integration model starts with finished product registration and supplies but often transitions into secondary packaging, followed by local filling and QC release, and eventually formulation filling and QC release. A further backward integration step of API/DS manufacturing is also possible in some cases.
For each stage from lab scale to pilot to commercial scales, our team ensures process optimization for higher yields while also focusing on batch-to-batch consistency based output, whether the tech transfer is within the organization or outsourced or out-licensed at any stage. We also assist you with licensing by conducting thorough due diligence, allowing you to close the deal with no stress.
TechInvention is committed to providing the best clinical trial management services for biologicals. These services allow healthcare companies to confidently try new things, make the most of opportunities, and improve global health.
Because biologicals are more complex than chemical drugs, both in composition and method of manufacture, the clinical trial process is equally complex. At TechInvention, we understand the challenges involved and have established all the necessary infrastructure needed to generate robust, clinically validated data for biologicals. We have invested our resources in clinically assessing biologicals against disease strains prevalent in the developing world, which bears 90% of the global burden of disease.
We also form clinical trial partnerships with governments, policymakers, multilateral and international organizations, the public-private sector, research and technical institutes, non-governmental organizations (NGOs), philanthropic organizations, and other like-minded organizations with the goal of long-term strengthening of public health systems and immunization programs in developing countries.